Selection of microbial T-cell epitopes for immune-diagnosis, immune-therapy and vaccine design

Current Pharmacogenomics

Volumn 3, Issue 4, 2005, Pages 247-257

  Seghrouchni, Fouad ^a,b   Berretta, Floriana ^a   Amicosante, Massimo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUT NATIONAL D HYGIÈNE   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EARLY SECRETORY ANTIGENIC TARGET 6; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B44 ANTIGEN; HLA B7 ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN CFP 10; T LYMPHOCYTE RECEPTOR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ALLELE; ANTIGEN STRUCTURE; ARTIFICIAL NEURAL NETWORK; AUTOIMMUNITY; AUTOMATION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BIOINFORMATICS; CELLULAR IMMUNITY; COMPUTER MODEL; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DATA ANALYSIS; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; GENETIC ANALYSIS; GENETIC CODE; GENETIC DATABASE; GENETIC POLYMORPHISM; HAPLOTYPE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION CONTROL; INFORMATION RETRIEVAL; INTERNET; LYMPHOCYTE PROLIFERATION; MALARIA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOGENOMICS; PLASMODIUM FALCIPARUM; PREDICTION; PROTEIN BINDING; PROTEIN DATABASE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; T LYMPHOCYTE; TUBERCULOSIS; VACCINE PRODUCTION; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM;

EID: 28444491510     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016005774913167     Document Type: Review

References (102)

1. Adams, H. P. and Koziol, J. A. (1995) Prediction of binding to MHC class I molecules. J. Immunol. Meth. 185, 181-190.
2. Altuvia, Y.; Schueler, O. and Margalit, H. (1995) Ranking potential binding peptides to MHC molecules by a computational threading approach. J. Mol. Biol. 249, 244-250.
3. Ahmad, S.; Amoudy, H. A.; Thole, J. E.; Young, D. B. and Mustafa, A. S. (1999) Identification of a novel protein antigen encoded by a Mycobacterium tuberculosis-specific RD1 region gene. Scand. J. Immunol. 49, 515-522.
4. Amicosante, M.; Gioia, C.; Montesano, C.; Casetti, R.; Topino, S.; D'Offizi, G.; Cappelli, G.; Ippolito, G.; Coalizzi, V.; Poccia, F. and Pupillo, L. P. (2002) Computer-Based Design of an HLA-Haplotype and HIV-Clade Independent Cytotoxic T-Lymphocyte Assay for Monitoring HIV-Specific Immunity. Mol. Med. 8, 798-807.
5. Al-Attiyah, R.; Shaban, F. A.; Wiker, H. G.; Oftung, F. and Mustafa, A. S. (2003) Synthetic peptides identify promiscuous human Th1 cell epitopes of the secreted mycobacterial antigen MPB70. Infect. Immun. 71, 1953-1960.
6. Anderton, S. M. (2001) Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 104, 367-376.
7. Berretta, F.; Butler, R. H.; Diaz, G.; Sanarico, N.; Arroyo, J.; Fraziano, M.; Aichinger, G.; Wucherpfennig, K. W.; Colizzi, V.; Saltini, C. and Amicosante, M. (2003) Detailed analysis of the effects of Glu/Lys β69 Human Leukocyte Antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens 62, 459-471.
8. Betts, M. R.; Casazza, J. P.; Patterson, B. A.; Waldrop, S.; Trigona, W.; Fu, T. M.; Kern, F.; Picker, L. J. and Koup, R. A. (2000) Putative immunodominant Human Immunodeficiency Virus-specific CD8+ T-cell responses cannot be predicted by Major Histocompatibility Complex class I haplotype. J. Virol. 74, 9144-9151.
9. Birkett, A.; Lyons, K.; Schmidt, A; Boyd, D; Oliveira, G. A.; Siddique, A.; Nussenzweig, R.; Calvo-Calle, J. M. and Nardin, E. A. (2002) Modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. 70, 6860-6870.
10. Borrás-Cuesta, F.; Golvano, J. J.; García-Granero, M.; Sarobe, P.; Riezu-Boj, J. I.; Huarte, E. and Lasarte, J. J. (2000) Specific and general HLA-DR binding motifs: comparison of algorithms. Human Immunology 61(3), 266-278.
11. Brown, J. H. (1995) Insight on the structure of MHC molecules. Acta Cryst. D. 51, 946-961.
12. Brusasca, P. N.; Colangeli, R.; Lyashchenko, K. P.; Zhao, X.; Vogelstein, M.; Spencer, J. S.; McMurray, D. N. and Gennaro, M. L. (2001) Immunological characterization of antigens encoded by the RD1 region of the Mycobacterium tuberculosis genome. Scand. J. Immunol. 54, 448-452.
13. Brusic, V.; Rudy, G.; Honeyman, M.; Hammer, J. and Harrison, L. C. (1998) Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14, 121-130.
14. Brusic, V.; Petrovsky, N.; Zhang, G. and Bajic, V. B. (2002) Prediction of promiscuous peptides that bind HLA class I molecules. Immunol. Cell Biol. 80(3), 280-285.
15. Brusic, V.; Bajic, V. B. and Petrovsky, N. (2004) Computational methods for prediction of T-cell epitopes - a framework for modelling, testing, and applications. Methods 34(4), 436-443.
16. Buxton, S. E.; Benjamin, R. J.; Clayberger, C.; Parham, P. and Krensky, A. M. (1992) Anchoring pockets in human histocompatibility complex leukocyte antigen (HLA) class I molecules: analysis of the conserved B ("45") pocket of HLA-B27. J. Exp. Med. 175, 809-820.
17. Carrara, S.; Vincenti, D.; Petrosillo, N.; Amicosante, M.; Girard, E. and Goletti, D. (2004) Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin. Infect. Dis. 38, 754-756.
18. Casazza, J. P.; Betts, M. R.; Picker, L. J. and Koup, R. A. (2001) Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Virol. 75, 6508-6516.
19. Carrington, M.; Nelson, G. W.; Martin, M. P.; Kissner, T.; Vlahov, D.; Goedert, J. J.; Kaslow, R.; Buchbinder, S.; Hoots, K. and O'Brien, S. J. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748-1752.
20. Castelli, F. A.; Buhot, C. and Sanson, A. (2002) HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169(12), 6928-6934.
21. Charo, J.; Geluk, A.; Sundback, M.; Mirzai, B.; Diehl, A. D.; Malmberg, K. J.; Achour, A.; Huriguchi, S.; van Meijgaarden, K. E.; Drijfhout, J. W.; Beekman, N.; van Veelen, P.; Ossendorp, F.; Ottenhoff, T. H. and Kiessling, R. (2001) The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. Eur. J. Immunol. 31, 3602-3611.
22. Charron, D. (2000) HLA 2000. Vox. Sang. 78(Suppl. 2), 27-28.
23. Chen, Y. Z.; Matsushita, S. and Nishimura, Y. (1996) Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J. Immunol. 157, 3783-3790.
24. Chen, L. (1999) Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Curr. Opin. Immunol. 11, 219-222.
25. Chicz, R. M.; Graziano, D.; Trucco, M.; Strominger, J. L. and Gorga, J. C. (1997) HLA-DP2. Self peptide sequences and binding properties. J. Immunol. 159, 4935-4942.
26. Cockle, P. J.; Gordon, S. V.; Lalvani, A.; Buddle, B. M.; Hewinson, R. G. and Vordermeier, H. M. (2002) Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect. Immun. 70, 6996-7003.
27. Dave, J. A.; Gey Van Pittius, N. C.; Beyers, A. D.; Ehlers, M. R. and Brown, G. D. (2002) Mycosin-1, a subtilisin-like serine protease of Mycobacterium tuberculosis, is cell wall-associated and expressed during infection of macrophages. BMC Microbiol. 7, 30.
28. Dawson, D. V.; Ozgur, M.; Sari, K.; Ghanayem, M. and Kostyu, D. D. (2001) Ramifications of HLA class I polymorphism and population genetics for vaccine development. Genet. Epidemiol. 20, 87-106.
29. De Groot, A. S.; Bosma, A.; Chinai, N.; Frost, J.; Jesdal, B. M.; Gonzales, M. A.; Martin, W. and Saint-Aubin, C. S. (2001) From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19, 4385-4395.
30. De Koster, H. S.; Vermeulen, C. J.; Hiemstra, H. S.; Amons, R.; Drijfhout, J. W. and Koning, F. (1999) Definition of agonists and design of antagonists for alloreactive T cell clones using synthetic peptide libraries. Int. Immunol. 11, 585-591.
31. Díaz, G.; Amicosante, M.; Jaraquemada, D.; Butler, R. H.; Guillen, M. V.; Sanchez, M.; Nombela, C. and Arroyo, J. (2003) Functional analysis of HLA-DP polymorphisms: crucial role for DPβ residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. Intern. Immunol. 15, 565-576.
32. Doytchinova, I. A.; Guan, P. and Flower, D. R. (2004) Quantitative structure-activity relationships and the prediction of MHC supermotifs. Methods 34(4), 444-453.
33. Esch, R. E. and Portnoy, J. (2001) Allergen immunotherapy. Curr. Allergy Asthma Rep. 1, 491-497.
34. Evavold, B. D.; Sloan-Lancaster, J. and Allen, P. M. (1993) Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today 14, 602-609.
35. Falcioni, F.; Ito, K.; Vidovic, D.; Belunis, C.; Campbell, R.; Berthel, S. J.; Bolin, D. R.; Gillespie, P. B.; Huby, N.; Olson, G. L.; Sarabu, R.; Guenot, J.; Madison, V.; Hammer, J.; Sinigaglia, F.; Steinmetz, M. and Nagy, Z. A. (1999) Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nat. Biotechnol. 17(6), 562-567.
36. Falk, K.; Rotzschke, O.; Stevanovic, S.; Jung, G. and Rammensee, H. G. (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324), 290-296.
37. Flower, D. R. (2003) Towards in silico prediction of immunogenic epitopes. Trends in Immunology 24(12), 667-674.
38. Forbes, B. A. (1997) Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Immunol. Invest. 26, 105-116.
39. Fraser, C. M.; Eisen, J. A. and Salzberg, S. L. (2000) Microbial genome sequencing. Nature 406, 799-803.
40. Gray, C.; Lawrence, J.; Schapiro, J. M.; Altman, J. D.; Winters, M. A., Crompton, M.; Loi, M.; Kundu, S. K.; Davis, M. M. and Merigan, T. C. (1999) Frequency of class I restricted anti-HIV CD8 T cells in individuals receiving highly active antiretroviral therapy. J. Immunol. 162, 1780-1788.
41. Graham, B. S. (2002) Clinical trials of HIV vaccines. Annu. Rev. Med. 53, 207-221.
42. Gulukota, K. and DeLisi, C. (1996) HLA allele selection for designing peptide vaccines. Genet. Anal. 13, 81-86.
43. Haan, E. C.; Moret, E. E.; Wagenaar-Hilbers, J. P.; Liskamp, R. M. and Wauben, M. H. (2005) Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy. Mol. Immunol. 42, 365-373.
44. Haan, E. C.; Wagenaar-Hilbers, J. P: Liskamp, R. M.; Moret, E. E. and Wauben, M. H. (2005) Limited plasticity in T cell recognition of modified T cell receptor contact residues in MHC class II bound peptides. Mol. Immunol. 42, 355-364.
45. Haro, I. and Somara, M. J. (2004) Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr. Protein Pept. Sci. 5(6), 425-433.
46. Honeyman, M. C.; Brusic, V.; Stone, N. L. and Harrison. L. C. (1998) Neural network-based prediction of candidate T-cell epitopes. Nat. Biotechnol. 16(10), 966-969.
47. Doytchinova, I. A.; Guan, P. and Flower, D. R. (2004) Identifiying Human MHC Supertypes Using Bioinformatic Methods. J. Immunology 172, 4314-4323.
48. Janeway, Jr. C. A.; Travers, P.; Walport, M. and Capra, J. D. (1999) Immunobiology: The Immune System in Health and Disease; Current Biology Publications: London, pp. 135.
49. Jardetzky, T. S.; Brown, J. H.; Gorga, J. C.; Stern, L. J.; Urban, R. G.; Strominger, J. L. and Wiley, D. C. (1996) Crystallographic analysis of endogenous peptides associated with HLA- DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl. Acad. Sci. USA 93, 734-738.
50. Jones, E. Y. (1997) MHC class I and class II structures. Curr. Opin. Immunol. 9, 75-79.
51. Kangueane, P.; Sakharkar; M. K.; Rajaseger, G.; Bolisetty, S.; Sivasekari, B.; Zhao, B.; Ravichandran, M.; Shapshak, P. and Subbiah, S. (2005) A framework to sub-type HLA supertypes. Front. Biosci. 10, 879-886.
52. Lalvani, A.; Nagvenkar, P.; Udwadia, Z.; Pathan, A. A.; Wilkinson, K. A. Shastri, J. S.; Ewer, K.; Hill, A. V.; Mehta, A. and Rodrigues, C. (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183, 469-477.
53. Larche, M. (2002) Anti-T-cell strategies in the treatment of allergic disease. Allergy 57(Suppl. 72), 20-23.
54. Lee, E. A.; Palmer, D. R.; Flanagan, K. L.; Reece, W. H.; Odhiambo, K.; Marsh, K.; Pinder, M.; Gravenor, M. B.; Keitel, W. A.; Kester, K. E.; Diggs, C., Kaslow, D.; Apostolopoulos, V.; Ballou, W. R.; Hill, A. V.; Krzych, U. and Plebanski, M. (2002) Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immun. 70, 1417-1421.
55. Lipford, G. B.; Hoffman, M.; Wagner, H. and Heeg, K. (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J. Immunol. 150, 1212-1222.
56. Lund, O.; Nielsen, M.; Kesmir, C.; Petersen, A. G.; Lundegaard, C.; Worning, P.; Sylvester-Hvid C.; Lamberth, K.; Røder, G.; Justesen, S.; Buus, S. and Brunak, S. (2004) Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics. 55, 797-810.
57. Mariani, F.; Cappelli, G.; Riccardi, G. and Colizzi, V. (2002) Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. Gene 253, 281-291,
58. Marino, M.; Ippolito, A.; Ruvo, M.; Scarallo, A.; Volpe, S. and Fassina, G. (2000) Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives. Mol. Immunol. 37, 951-960.
59. McMichael, A. J. and Rowland-Jones, S. L. (2001) Cellular immune response to HIV. Nature 410, 980-987.
60. Meidenbauer, N.; Marienhagen, J.; Laumer, M.; Vogl, S.; Heymann, J.; Andreesen, R. and Mackensen A. (2003) Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170, 2161-2169.
61. Miller, S. M.; Simon, R. J.; Ng, S.; Zuckermann, R. N.; Kerr, J. M. and Moos, W. H. (1994) Proteolytic studies of homologous peptide and Nsubstituted glycine peptoid oligomers. Bioorg. Med. Chem. Lett. 4, 2657-2662.
62. Mrowietz, U. (2002) Treatment targeted to cell surface epitopes. Clin. Exp. Dermatol. 27, 591-596.
63. Mustafa, A. S.; Cockle, P. J.; Shaban, F.; Hewinson, R. G. and Vordermeier, H. M. (2002) Immunogenicity of Mycobacterium tuberculosis RD1 region gene products in infected cattle. Clin. Exp. Immunol. 130, 37-42.
64. Mustafa, A. S. and Al-Attiyah, R. (2003) Tuberculosis: looking beyond BCG vaccines. J. Postgrad. Med. 49, 134-140.
65. Natarajan, K.; Li, H.; Mariuzza, R. A. and Margulies, D. H. (1999) MHC class I molecules, structure and function. Rev. Immunogenet. 1(1), 32-46.
66. Nicholson, L. B.; Greer, J. M.; Sobel, R. A.; Lees, M. B. and Kuchroo, V. K. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3, 397-405.
67. Nussbaum, A. K.; Kuttler, C.; Hadeler, K. P.; Rammensee, H. G. and Schild, H. (2001) PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53, 87-94.
68. Okkels, L. M.; Brock, I.; Follmann, F.; Agger, E. M.; Arend, S. M.; Ottenhoff, T. H.; Oftung, F.; Rosenkrands, I. and Andersen, P. (2003) PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect. Immun. 71, 6116-6123.
69. Ou, D.; Mitchell, L. A. and Tingle, A. J. (1998) A new categorization of HLA-DR alleles on a functional basis. Hum. Immunol. 59, 665-676.
70. Paas-Rozner, M.; Sela, M. and Mozes, E. (2001) The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc. Natl. Acad. Sci. USA 98, 12642-12647.
71. Parker, K. C.; Bednarek, M. A. and Coligan, J. E. (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175.
72. Pheiffer, C.; Betts, J.; Lukey, P. and van Helden, P. (2002) Protein expression in Mycobacterium tuberculosis differs with growth stage and strain type. Clin. Chem. Lab. Med. 40, 869-875.
73. Pieters, J. MHC class II restricted antigen presentation. (1997) Curr. Opin. Immunol. 9, 89-96.
74. Pym, A. S.; Brodin, P.; Majlessi, L.; Brosch, R.; Demangel, C.; Williams, A.; Griffiths, K. E.; Marchal, G.; Leclerc, C. and Cole, S. T. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9, 533-539.
75. Rammensee, H. G. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85-96.
76. Rammensee, H. S.; Bachmann, J.; Emmerich, N. N.; Bachor, O. A. and Stevanovic, S. (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219.
77. Ravn, P.; Demissie, A.; Eguale, T.; Wondwosson, H.; Lein, D.; Amoudy, H. A.; Mustafa, A. S.; Jensen, A. K.; Holm, A.; Rosenkrands, I.; Oftung, F.; Olobo, J.; von Reyn, F. and Andersen, P. (1999) Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179, 637-645.
78. Rotzschke, O. and Falk, K. (1991) Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol. Today 12, 447-455.
79. Rudolph, M. G. and Wilson, I. A. (2002) The specificity of TCR/pMHC interaction. Curr. Opin. Immunol. 14, 52-65,
80. Ruiz, P. J.; DeVoss, J. J.; Nguyen, L. V.; Fontoura, P. P., Hirschberg, D. L.; Mitchell, D. J.; Garcia, K. C. and Steinman, L. (2001) Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs. J. Immunol. 167, 2688-2693.
81. Sakaguchi, H.; Inoue, R.; Kaneko, H.; Watanabe, M.; Suzuki, K.; Kato, Z.; Matsushita, S. and Kondo, N. (2002) Interaction among human leucocyte antigen-peptide-T cell receptor complexes in cow's milk allergy: the significance of human leucocyte antigen and T cell receptor-complementarity determining region 3 loops. Clin. Exp. Allergy 32, 762-770.
82. Santodonato, L.; D'Agostino, G.; Nisini, R.; Mariotti, S.; Monque, D. M.; Spada, M.; Lattanzi, L.; Perrone, M. P.; Andreotti, M.; Belardelli, F. and Ferrantini, M. (2003) Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170, 5195-5202.
83. Sette, A. and Sidney, J. (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10, 478-482.
84. Sette, A. and Sidney, J. (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50, 201-212.
85. Schipper, R. F.; van Els, C. A.; D'Amaro, J. and Oudshoorn, M. (1996) Minimal phenotype panels: a method for achieving maximum population coverage with a minimum of HLA antigens. Hum. Immunol. 51, 95-98.
86. Sidney, J.; Southwood, S.; Mann, D. L.; Fernandez-Vina, M. A.; Newman, M. J. and Sette, A. (2001) Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum. Immunol. 62, 1200-1216.
87. Singh, H. and Raghava, G. P. S. (2001) ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17, 1236-1237.
88. Sinigaglia, F. and Hammer, J. (1994) Defining rules for the peptide-MHC class II interaction. Curr. Opin. Immunol. 6, 52-56.
89. Sinigaglia, F. and Hammer, J. (1995) Predicting major histocompatibility complex-binding sequence within protein antigens. Biochem. Soc. Trans. 23, 675-676.
90. Sospedra, M.; Pinilla, C. and Martin, R. (2003) Use of combinatorial peptide libraries for T-cell epitope mapping. Methods 29(3), 236-247.
91. Southwood, S.; Sidney, J.; Kondo, A.; del Guercio, M. F.; Appella, E.; Hoffman, S.; Kubo, R. T.; Chesnut, R. W.; Grey, H. M. and Sette, A. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363-3373.
92. Sturniolo, T.; Bono, E.; Ding, J.; Raddrizzani, L.; Tuereci, O. and Sahin, U. (1999) Generation of tissus-specific promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nat. biotech. 17, 555-561.
93. Vajda, S. and Delisi, C. (1990) Determining minimum energy conformations of polypeptides by dynamic programming. Biopolymers 29, 1755-1772.
94. Vincenti, D.; Carrara, S.; De Mori, P.; Pucillo, L. P.; Petrosillo, N.; Palmieri, F.; Armignacco, O.; Ippolito, G.; Girardi, E.; Amicosante, M. and Goletti, D. (2003) Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol. Med. 9, 105-111.
95. Walker, B. D. and Korber, B. T. (2001) Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2, 473-475.
96. Wang, Y.; Lin, H.; Tullman, R.; Jewell, Jr. C. F.; Weetall, M. L. and Tse, F. L. S. (1999). Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Biopharm. Drug Dispos. 20, 69-75.
97. Wauben, M. H. M.; Boog, C. J. P.; van der Zee, R.; Joosten, I.; Schlief, A. and van Eden, W. (1992) Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176, 667-677.
98. Weathington, N. M. and Blalock, J. E. (2003) Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev. Vaccines 2, 61-73.
99. Wilson, D. B.; Pinilla, C.; Wilson, D. H.; Schroder, K.; Boggiano, C.; Judkowski, V.; Kaye, J.; Hemmer, B.; Martin, R. and Houghten, R. A. (1999) Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. J. Immunol. 163, 6424-6434.
100. Yu, X. G.; Addo, M. M.; Rosenberg, E. S.; Rodriguez, W. R.; Lee, P. K.; Fitzpatrick, C. A. and Johnston, M. N. (2002) Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J. Virol. 76, 8690-8701.
101. Yu, K.; Petrovsky, N.; Schönbach, C.; Koh, J. L. Y. and Brusic, V. (2002) Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study. Molecular Medicine 8(3), 137-148.
102. Zhao, B.; Png, A. E.; Ren, E. C.; Kolatkar, P. R.; Mathura, V. S.; Sakharkar, M. K. and Kangueane, P. (2003) Compression of functional space in HLA-A sequence diversity. Hum. Immunol. 64, 718-728.